STRO: Ascending Triangle detected on 27 Mar 2026
Overall Score
78
of 100
Good
Win Probability
63%
Moderate
Reward / Risk
1.2
: 1
$0.44 reward
$-0.36 risk
Current Setup
STRO is forming an ascending triangle with initial clinical data from STRO-004 expected in mid-2026 and an IND submission for dual-payload program STRO-227 targeted for 2026. At $24.91, the stock is testing key resistance at $26.22 with support at $19.21 — a 373% move from the 52-week low. The breakout score of 13.0 and structure score of 13.75 indicate a moderately defined pattern, though volume at 0.94 relative to average is slightly weak. Overall score of 77.95 and win probability of 62.83% suggest a tradeable setup with moderate conviction.
Stock Context
Sutro reported on March 23, 2026 that cash of $141.4 million, excluding $110 million from a recent capital raise, extended cash runway into at least Q2 2028. HC Wainwright upgraded STRO from neutral to buy with a $28 price target, and Wells Fargo upgraded from equal weight to overweight with a $27 target. Revenue rose to $102.5 million in 2025 from $62.0 million in 2024, driven principally by Astellas and Ipsen collaboration payments. An Astellas partnership for dual-payload iADCs entered the clinic with patient dosing underway, expected to trigger a $10 million milestone in Q2 2026. This near-term clinical catalyst and expanded cash runway align with the stock's 22% one-month gain, suggesting institutional repositioning into the pattern.
What to Expect
An ascending triangle breakout above $26.22 would target the conservative measure of $26.44, though historical ADC biotech patterns often extend 15–25% beyond initial resistance in strong momentum conditions. Volume confirmation is critical — breakout validity requires volume exceeding 215,695 shares (20-day average) to validate the move. Invalidation occurs below $19.21, the key support level where the pattern structure breaks. The 62.83% win probability indicates roughly two-in-three chance of a profitable breakout within the pattern timeframe.
Risk Factors
STRO reported an EPS miss on March 23, reporting ($5.39) versus consensus of ($4.66), though Q4 revenue of $11.65 million beat consensus of $9.26 million. The company carries a negative net margin of 206.77% and negative return on equity of 852.70%, typical of clinical-stage biotech but indicating heavy cash burn. RSI at 65.83 is approaching overbought territory (>70), flagging potential near-term profit-taking. Insider lockup agreements expire May 12, 2026, creating a post-catalyst overhang risk. The broader bearish market regime (score -0.43) and bearish health-care sector regime (-0.09) mean downside breaks could accelerate if clinical data disappoint in mid-2026.
Sources:
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering :: Sutro Biopharma, Inc. (STRO)
·
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights
·
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights
·
Sutro Biopharma to Participate in Upcoming Investor Conferences :: Sutro Biopharma, Inc. (STRO)
·
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering
·
Press Releases :: Sutro Biopharma, Inc. (STRO)
·
Sutro Biopharma to Participate in Upcoming Investor Conferences
·
Sutro Biopharma (NASDAQ:STRO) Announces Quarterly Earnings Results - Daily Political
·
Latest STRO News - Sutro Biopharma Reports Full Year 2025 Fina...
·
STRO: Reverse Split And Equity Raise Will Support Future Upside
·
Sutro Biopharma (NASDAQ:STRO) Announces Quarterly Earnings Results - Daily Political
·
Deutsche Bank Aktiengesellschaft Issues Positive Forecast for Sutro Biopharma (NASDAQ:STRO) Stock Price - Markets Daily
·
Revenue jumps as Sutro Biopharma (NASDAQ: STRO) narrows 2025 loss
·
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights
·
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights - BioSpace
·
Sutro Biopharma, Inc. (STRO) Stock Price, News, Quote & History - Yahoo Finance
·
Sutro Biopharma (NASDAQ:STRO) Issues Earnings Results
·
Sutro Biopharma posts 2025 results, runway to 2028 | STRO Stock News
·
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights
·
Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights :: Sutro Biopharma, Inc. (STRO)
Market & Sector Regime
Market
Bearish
-0.43
-1.0
0
+1.0
Health Care Sector
Bearish
-0.09
-1.0
0
+1.0
Other Patterns Detected Today
Bull Flag
32 days in pattern
Weak
25.7
Rounding Bottom
180 days in pattern
Good
33.7
Overall Score
37
of 40
Pattern Quality
18
of 20
Setup
11
of 20
R/R
12
of 18
Context
Pattern Quality Score
14
of 15
Structure
13
of 13
Breakout
10
of 12
Volume
Recent Performance
Momentum & Trend
RSI (14)
65.8
Neutral
MACD Histogram
-0.17
Bearish
Bollinger Band Position
79.3%
Upper Zone
Volatility & Risk
20-Day Volatility
0.81
Very High
ATR %
9.5%
High
Beta
1.08
Market
Volume Analysis
Volume Ratio
0.94x
Average
20-Day Avg Vol
216K
shares / day
Current Volume
202K
shares traded
Price Levels
52W High
$26.54
Target
$26.44
Resistance
$26.22
Current
$24.91
Stop Loss
$22.64
Support
$19.21
52W Low
$5.23
Disclaimer: This analysis is algorithmically generated for educational purposes only and does not constitute financial advice. Past pattern performance does not guarantee future results. Win probabilities are based on historical data across 370,000+ observations. Always conduct your own research and consult a qualified financial advisor. AI-assisted contextual analysis by Claude (Anthropic). Indicators reflect values at time of detection.